Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Pilot Randomized Controlled Study of a Smartphone Delivered Progressive Muscle Relaxation Intervention for Migraine in Primary Care
Headache
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-011

To improve access and outcomes, we assessed the feasibility and acceptability of a smartphone application (app) based Progressive Muscle Relaxation (PMR) intervention for the self-management of migraine in  primary care.  

PMR is an under-utilized Level A evidence-based treatment for migraine prevention, rarely available in primary care.

We randomized adults with migraine with 4+ headache days/month who owned a smartphone into one of two groups: Group 1 received the app with only a headache diary and Group 2 received the app with a headache diary + PMR. The latter group was asked to do PMR up to 20 minutes/day. Outcomes included satisfaction levels and adherence to the PMR intervention (frequency and duration), frequency of diary entries. Exploratory outcomes included change in headache days and change in the Migraine Disabling Assessment (MIDAS) scale scores.

Of the 139 patients (77 PMR, 62 placebo), 83% were female, mean age was 41.7 ± 12.8 years.  Most were disabled by their migraine (MIDAS 53% severe, 25% moderate disability).  PMR was played for 19+1 days out of 90-days. Mean per session duration was 11+8 minutes.  For the first 6 weeks, participants did PMR 2-4 days/week but adherence declined thereafter. When comparing weekly headache days reported in PMR versus control arms, we observed 3 fewer headache days in the PMR arm (p = 0.45).  Relative to the diary only group, the PMR group showed a greater decline in MIDAS scores that was not statistically significant  (-22.8 vs. -8.7, P=0.1). However, mean effect size showed a moderate change (cohen’s d=0.38, p=0.98).

 

 

Preliminary data suggests that smartphone delivered PMR may be an acceptable, accessible form of evidence-based therapy for migraine that can be offered in primary care. Future work should revise the app to improve adherence and assess larger sample sizes measuring efficacy outcomes.

Authors/Disclosures
Mia T. Minen, MD, FÂé¶¹´«Ã½Ó³»­ (NYULMC Neurology)
PRESENTER
The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .
No disclosure on file
No disclosure on file
Eric J. Goldberg, MD (Tidewater Neurology) No disclosure on file
Scott Powers, PhD (Cincinnati Children's Hospital) Scott Powers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Scott Powers, PhD has received research support from NIH. The institution of Scott Powers, PhD has received research support from PCORI. The institution of Scott Powers, PhD has received research support from Cystic Fibrosis Foundation. Scott Powers, PhD has a non-compensated relationship as a Associate Editor with The Journal HEADACHE that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Scott Powers, PhD has a non-compensated relationship as a Member Board of Directors with American Headache Society that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
Richard B. Lipton, MD, FÂé¶¹´«Ã½Ó³»­ (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.